[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure-high\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure-high":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,72,103,137,162,187,214,242],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100639457","impact-htn-study-of-patients-with-hypertension-100639457",false,"NCT07579260","IMPACT-HTN Study of Patients With Hypertension","Prospective Early Patient Experience Initiative (IMPACT-HTN)","Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Ability to answer survey questions and to report blood pressure reading monthly\n* Male and female participants; 18 years or older\n* Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit\n* Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg\n\nExclusion Criteria:\n\n* Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and\u002For Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg\n* Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator\n* Heart failure NYHA functional class III and IV or NT-proBNP \\> 500 pg\u002FmL\n* Severe renal insufficiency or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2\n* Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\\> 3 x ULN)","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","97 Days","OBSERVATIONAL","An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.",[25,26,27],"Hypertension (HTN)","Hypertension","Blood Pressure, High","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":20},"2026-07-01",{"date":36,"type":20},"2027-04-01",{"name":38,"class":39},"Vivek Bhalla","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100609716","clinical-decision-support-tool-for-the-treatment-of-uncontrolled-hypertension-100609716","NCT07218198","Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension","A Stepped Wedged, Cluster Randomized Clinical Trial to Evaluate the Efficacy of a Clinical Decision Support Tool in the Treatment of Uncontrolled Hypertension","AI-HTN","Inclusion Criteria:\n\n1. Men and women 18 years of age or older\n2. Electronic Health Record (EHR) of hypertension AND prescribed at least one BP lowering medication\n3. Office systolic BP of 130 mmHg or higher\n4. Willing and able to comply with the study instructions AND attend a scheduled study visit\n\nExclusion Criteria:\n\n1. Women who are pregnant, plan to become pregnant, or are breast-feeding\n2. Know heart failure with reduced ejection fraction and a left ventricular ejection fraction of less than 40%\n3. End-stage kidney disease currently undergoing renal replacement therapy, or an eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2\n4. In the opinion of the investigator, any other condition that will preclude participation in the study",{"count":50,"type":20},168,"INTERVENTIONAL",[53],"NA","The goal of this clinical trial is to study whether having a clinical decision support (CDS) tool available to clinician use will more effectively lower BP 4 weeks after an outpatient visit compared with usual care. The main objective is to assess the impact of the CDS tool, that is embedded with the electronic medical record (EMR), that is available during outpatient clinical encounters, on blood pressure (BP) changes among participants with uncontrolled hypertension.\n\nParticipants will:\n\nVisit the clinic 4 weeks, after their initial clinician visit, for a BP check.",[26,25,27,56],"Blood Pressure Control",[58,26,59,60,61,62],"Uncontrolled Hypertension","Blood Pressure","High Blood Pressure","Artificial Intelligence","AI","2026-04-27",{"date":65,"type":32},"2026-04-28",{"date":34,"type":20},{"date":68,"type":20},"2027-12-01",{"name":70,"class":39},"The Cleveland Clinic",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":51,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100537740","early-phase-1-cognitive-behavioral-therapy-and-trazodone-effects-on-sleep-and-blood-pressure-in-insomnia-100537740","NCT06281756","Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia","Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort\u002FRandomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 or older\n* Able to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site.\n* Meets criteria for chronic insomnia\n* Body Mass Index (BMI) 18.5 kg\u002Fm2 and higher\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Unable to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site.\n* Unwilling to share email address\u002Fcell phone number to accept survey links.\n* Life time diagnosis of psychotic or bipolar disorder\n* History of severe apnea or an Apnea Hypopnea Index (AHI) ≥15 that is not currently treated with Positive Airway Pressure (PAP) therapy, an oral device or an implanted device, or was not treated with surgery or weight loss.\n* Started new or changed treatment for sleep apnea in the past three months\n* Does not meet criteria for chronic insomnia\n* Meets criteria for narcolepsy or hypersomnia disorder\n* Meets criteria for circadian rhythm disorder (including night shift work)\n* Unstable medical conditions that would make participation unsafe or unfeasible\n* Falls resulting in hospitalization, significant injury or fracture within past 12 months\n* 2 hospitalizations or emergency room visits within past 12 months for chronic conditions\n* Active chemotherapy or radiation therapy for cancer\n* Lifetime diagnoses\u002Ftreatment of chronic renal failure, hepatic insufficiency, chronic heart failure\n* Does not agree to refrain from other treatments for insomnia beyond what is offered in this study\n* BMI less than 18.5\n* Substance abuse or dependence in the past 12 months\n* Current use of prescription or over the counter medications taken for sleep greater than 2 times per week\n* Current use of systemic corticosteroids or opiate medications\n* Current pregnancy or breastfeeding; plans to get pregnant or unwillingness to use birth control for the length of the study\n* Current use of medications contraindicated with trazodone\n* Sleep apnea or periodic leg movement disorder as determined by sleep study\n* Blood Pressure levels defined as seated SBP greater than 180 or DBP greater than 110 mmHg\n* EKG corrected QT interval greater than or equal to 500 ms",{"count":80,"type":20},600,[82],"EARLY_PHASE1","Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.",[85,86,87,59,27],"Insomnia","Insomnia Chronic","Insomnia, Primary",[89,90,91],"sleep","sleep disorder","insomnia","RECRUITING","2025-11-06",{"date":95,"type":32},"2025-11-10",{"date":97,"type":32},"2024-03-20",{"date":99,"type":20},"2028-05-31",{"name":101,"class":39},"Milton S. Hershey Medical Center",4,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":51,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":71},"100581069","impact-of-resistance-training-intensity-on-blood-pressure-100581069","NCT06845514","Impact of Resistance Training Intensity on Blood Pressure","High Blood Pressure and Effect of Acute Resistance Training: Influence of Different Load Intensities on Postexercise Hypotension and Ambulatory Blood Pressure in Aging Females","HEART","Inclusion Criteria:\n\n* aged 50 to 70 years;\n* absence of menstruation for 12 consecutive months;\n* normal-high resting blood pressure (120 ≤ Systolic ≤ 139 mmHg and 80 ≤ Diastolic ≤ 89 mmHg) or stage 1 hypertension (140 ≤ Systolic ≤ 159 mmHg or 90 \\\u003C Diastolic ≤ 99 mmHg);\n* physically inactive (\\\u003C 150 minutes of structured aerobic physical activity per week);\n* and not engaging in regular resistance exercise (≥ 2 sessions per week) for more than 3 months during the year.\n\nExclusion Criteria:\n\n* orthopedic limitations or other contraindications to resistance exercise;\n* scheduled surgery during the study;\n* unstable hypertension (≥ 160\u002F100 mmHg);\n* diagnosis of type 2 diabetes;\n* cardiovascular event in the past 6 months or sequelae preventing exercise;\n* and initiation of hormonal replacement therapy (\\\u003C 4 months) known to affect blood pressure.",true,"FEMALE","50 Years","70 Years",{"count":116,"type":20},36,[53],"The goal of the clinical trial is to understand the effect of two resistance training protocols employing different loading intensities (% of 1 repetition maximum; 1-RM), but with standardized effort intensity (2 repetitions in reserve; RIR) on post-exercise and ambulatory blood pressure in aging females.\n\nThe main questions it aims to answer are:\n\n* to examine the acute effects of low (50% 1-RM) and high (80% 1-RM) load intensity resistance exercise with a standardized high effort intensity on post-exercise hypotension and ambulatory blood pressure responses in aging females;\n* deepen the understanding of the mechanisms underlying acute reductions in blood pressure in response to resistance exercise performed at different load intensities. To this end, autonomic activity will be estimated alongside the measurement of central arterial compliance (i.e., carotid artery), and serum biomarkers of endothelial function;\n* document the affective valence and enjoyment associated with low (50% 1-RM) and high (80% 1-RM) load intensity resistance exercise when performed at a high perceived effort.\n\nResearchers will compare the effect of: 1) a low load (LL-RE) intensity protocol consisting of 3 sets of each exercise at 50% 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2); 2) high load (HL-RE) intensity protocol consisting of 3 sets of each exercise at 80% of 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2); 3) and a control condition (CON) consisting of a standardized non-fatiguing cognitive task.\n\nParticipants will participate in:\n\n* A preliminary assessment visit;\n* Two familiarization visits to validate the exercise prescriptions;\n* Three experimental visits (CON, LL-RE, HL-RE).",[120,121,27,59],"Blood Pressure Management","Blood Pressure Monitoring, Ambulatory",[123,124,125,126,127],"resistance training","ambulatory blood pressure","aging females","load intensity","perceived effort","2025-09-02",{"date":130,"type":32},"2025-09-09",{"date":132,"type":32},"2025-07-08",{"date":134,"type":20},"2028-12",{"name":136,"class":39},"Université de Sherbrooke",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":51,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":71},"100555583","validation-study-of-cart-bp-as-a-wearable-cuffless-blood-pressure-monitor-100555583","NCT06513975","Validation Study of CART BP as a Wearable Cuffless Blood Pressure Monitor","Validation Study of CART BP as a Wearable Cuffless Blood Pressure Monitor: Evaluation of Blood Pressure Measurement by Height and Physical Activity","Inclusion Criteria:\n\n* Subjects aged 18 years or older but younger than 80 years\n* Individuals who voluntarily decide to participate in this clinical trial and provide written consent to the information and consent form\n* Individuals willing to comply with the clinical trial protocol\n\nExclusion Criteria:\n\n* Subjects who do not consent to the study\n* Obese individuals with a Body Mass Index (BMI) of 30 or higher (concerns about measurement errors as the standard 24-hour ambulatory blood pressure monitor cuff may not fit the arm properly)\n* Patients or volunteers who are pregnant\n* Patients or volunteers with underlying heart diseases: those with a history of hospitalization for heart failure, valvular disease, or myocardial infarction\n* Patients or volunteers diagnosed with atrial fibrillation on a 12-lead electrocardiogram (ECG) within the past 6 months\n* Patients or volunteers with end-stage renal disease (undergoing dialysis)\n* Patients or volunteers unable to perform repeated exercises required for the study\n* Patients or volunteers with a systolic blood pressure (SBP) exceeding 160 millimeters of mercury (mmHg)\n* Patients or volunteers with a systolic blood pressure (SBP) exceeding 160 millimeters of mercury (mmHg) and\u002For a diastolic blood pressure (DBP) exceeding 100 millimeters of mercury (mmHg) (for exercise tests)","80 Years",{"count":146,"type":20},50,[53],"This study aims to evaluate the accuracy of the CART BP, a medically approved ring-type blood pressure monitor, in comparison to the traditional auscultatory method using a dual-head stethoscope. The comparison is conducted in accordance with the 2023 European Society of Hypertension (ESH) Recommendations, focusing on patients with suspected hypertension or hypotension. The evaluation includes accuracy measurements across various postures and during different exercise periods.",[59,26,27,150,151],"Blood Pressure, Low","Hypotension","2025-06-11",{"date":154,"type":32},"2025-06-15",{"date":156,"type":32},"2024-11-22",{"date":158,"type":20},"2025-08-15",{"name":160,"class":161},"Sky Labs","INDUSTRY",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":114,"enrollmentInfo":170,"targetDuration":4,"studyType":51,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":71},"100592059","goal-setting-and-mobile-based-self-management-tool-to-improve-diet-quality-of-people-with-high-blood-pressure-100592059","NCT06988501","Goal Setting and Mobile-based Self-management Tool to Improve Diet Quality of People With High Blood Pressure","The Effect of Goal Setting With Mobile-based Self-management Tool on Improving Diet Quality of People With High Blood Pressure: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 20-70;\n* Hypertension diagnosis, or high blood pressure (SBP between 120-139 mmHg and\u002For DBP between 80-89 mmHg);\n* Eating an unhealthy diet (estimated DASH score \\\u003C 6) ;\n* Owning a smartphone and able to operate it proficiently;\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Severe cardiovascular and respiratory diseases, such as acute myocardial infarction, tachyarrhythmia, pulmonary edema, and severe aortic stenosis;\n* Acute phase of cardiovascular and cerebrovascular diseases;\n* Uncontrolled blood pressure;\n* Diagnosed mental diseases or epilepsy;\n* Cardiac pacemaker implantation;\n* Allergic constitutions;\n* Pregnant women or planning to become pregnant;\n* Individuals who have participated in other clinical studies within the past 3 months;\n* Refuse to sign the informed consent.","20 Years",{"count":171,"type":20},110,[53],"SMART goal setting is a patient-led method that can help improve execution and facilitate behavioral changes. Functions such as diet tracking, interaction, and feedback in smartphone application may help enhance patient compliance. This study aims to explore the nutrition intervention measures of SMART goal setting combined with smartphone applications for daily self-management on the effect of improving diet quality of people with high blood pressure.",[27],[176],"goal setting","2025-05-16",{"date":179,"type":32},"2025-05-25",{"date":181,"type":32},"2024-07-02",{"date":183,"type":20},"2025-12-31",{"name":185,"class":186},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":51,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":71},"100526262","in-hospital-detection-of-elevated-blood-pressure-100526262","NCT06132451","In-Hospital Detection of Elevated Blood Pressure","In-Hospital Detection of Elevated Blood Pressure (INDEBP): Prevalence of New or Uncontrolled Hypertension and Safety of Postponement of Antihypertensive Treatment Adaption in Medical In-patients","INDEBP","Inclusion Criteria:\n\n* Patient hospitalized on the internal medicine ward for non-cardiovascular causes, i.e. patients hospitalized for conditions, which are not acutely worsened by uncontrolled AHT\n* Asymptomatic elevated BP values (defined as 140-180 mmHg systolic and\u002For 90-110 mmHg diastolic) on at least 2 occasions\n* Ability to understand study procedures and to provide written informed consent\n\nExclusion Criteria:\n\n* Hospitalization for any conditions which can be worsened by uncontrolled AHT:\n* Cerebrovascular events\n* Acute coronary syndrome\n* Acute or decompensated heart failure\n* Any condition preventing ABPM\n* Pregnant or lactating women\n* Failure to provide informed consent",{"count":196,"type":20},800,[53],"The goal of this clinical trial is to analyse the prevalence of new or uncontrolled arterial hypertension (AHT) after hospital discharge of medical in-patients with elevated blood pressure (BP) values during hospitalisation.\n\nThe main questions it aims to answer are:\n\n* Do elevated BP values during hospitalisation correspond to new or uncontrolled AHT after hospital discharge?\n* Is it safe to postpone adaption of antihypertensive treatment until after proper evaluation of AHT after hospital discharge?\n\nParticipants will either be treated according to their physicians' decision or antihypertensive treatment adaptions will be postponed until after hospital discharge.",[26,27],[201,202,203,204],"arterial hypertension","elevated blood pressure","ambulatory blood pressure measurement","antihypertensive medication","2024-09-16",{"date":207,"type":32},"2024-09-19",{"date":209,"type":32},"2023-11-16",{"date":211,"type":20},"2024-12-31",{"name":213,"class":39},"Annina Vischer",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":71},"100523638","effects-of-change-in-blood-pressure-on-retinal-capillary-rarefaction-in-patients-with-arterial-hypertension-100523638","NCT06098300","Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension","Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study","Inclusion Criteria:\n\n* Men and Women aged ≥ 18 years\n* Signed informed consent\n* Apart from hypertensive retinopathy, normal ophthalmic findings\n* Non-Smokers\n* Patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmHg and\u002For diastolic office blood pressure ≥ 90 mmHg)\n* Planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the Department of Cardiology\n* Subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the three weeks preceding the study\n* Blood donation in the three weeks preceding the study\n* Symptoms of a clinically relevant illness in the three weeks preceding the study\n* History of family history of epilepsy\n* Secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, Cushing-syndrome, Coarctatio aortae)\n* History of hypertensive encephalopathy or intracerebral bleeding\n* Diabetes mellitus Type 1 or Type 2\n* Pregnant or breast-feeding women\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception","90 Years",{"count":223,"type":20},30,"To evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.",[226,27],"Arterial Hypertension",[228,26,229,230,231,232,233],"Retinal Capillary Rarefaction","Antihypertensive medication","OCT-A","Retinal oxygen extraction","Choroidal vascularity index (CVI)","Ocular blood flow","2024-09-05",{"date":207,"type":32},{"date":237,"type":32},"2023-09-01",{"date":239,"type":20},"2025-08",{"name":241,"class":39},"Medical University of Vienna",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":71},"100345971","metabolic-and-bone-changes-after-adjuvant-cancer-treatments-in-early-non-metastatic-breast-cancer-100345971","NCT03784651","Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer","Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.","Inclusion Criteria:\n\n* Postmenopausal\n* Breast cancer stage I-III\n* Eligible to receive (neo-)adjuvant chemotherapy\u002Fother antineoplastic treatment\n\nExclusion Criteria:\n\n* Prior malignancy\n* Metabolic disease (diabetes mellitus etc)",{"count":250,"type":20},120,"Breast cancer is the most common cancer type in European women. Patients treated for early non-metastatic breast cancer comprise a growing group of survivors due to early diagnosis and improved treatment. Many of these survivors experience adverse effects such as decreased bone mineral density, derangement of metabolic markers (fat, glucose, insulin) and increased blood pressure. Increasing risk of bone fracture and cardiometabolic disease (eg. diabetes mellitus type 2).\n\nThe purpose of this study is to identify mechanisms behind cardiometabolic changes that may be connected to the (neo-)adjuvant treatment. On top of this we hope to indentify potential biological markers that can help prevent development of metabolic disease.\n\nWe will be recruiting 120 post-menopausal women age 50-70 with early breast cancer and 1-2 times a year for 5 years examine bone mineral density, body composition, glucose and fat metabolism and nerve damage. A questionnaire will be used to collect information on diet, physical activity and quality of life. Derudover anvendes spørgeskemaer til at indsamle information vedrørende. This new knowledge will help clinicians start adequate preventive measures to help patients avoid cardiometabolic disease secondary to cancer treatment.",[253,254,255,27,256],"Bone Fracture","Glucose, High Blood","Insulin Resistance","Cholesterolemia","2021-09-14",{"date":259,"type":32},"2021-09-16",{"date":261,"type":32},"2018-12-17",{"date":263,"type":20},"2026-11",{"name":265,"class":39},"Rigshospitalet, Denmark"]